Novartis aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021

1 minute read

The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann

Register now for FREE unlimited access to Reuters.com

ZURICH, June 22 (Reuters) - Novartis aims to help manufacture more than 50 million doses of BioNTech's (22UAy.DE) COVID-19 vaccine in 2021 at its Stein, Switzerland fill-and-finish facility, the Swiss drugmaker said, after the European Union's drug regulator approved the bottling plant.

Register now for FREE unlimited access to Reuters.com
Reporting by John Miller Editing by Chris Reese

Our Standards: The Thomson Reuters Trust Principles.